Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases, with a particular emphasis on autoimmune kidney disorders such as immunoglobulin A nephropathy (IgAN). The VERA news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow key clinical, regulatory, and corporate developments affecting the stock.
News about Vera Therapeutics frequently centers on its lead product candidate, atacicept, an investigational fusion protein targeting BAFF and APRIL. Recent announcements include submission and U.S. FDA Priority Review of a Biologics License Application for atacicept in adults with IgAN, supported by data from the ORIGIN Phase 2b and ORIGIN 3 Phase 3 trials. The company has highlighted statistically significant and clinically meaningful reductions in proteinuria and a safety profile described as comparable to placebo, as well as presentations at major scientific meetings and publication of trial results in The New England Journal of Medicine.
Investors and followers of VERA stock can also expect news on pipeline expansion and broader immunology programs. Vera Therapeutics reports ongoing evaluation of atacicept in expanded IgAN populations and other autoimmune kidney diseases, along with development of VT-109, a next-generation BAFF/APRIL-targeting fusion protein licensed from Stanford University, and MAU868, a monoclonal antibody designed to neutralize BK virus infection in kidney transplant recipients.
In addition, the news flow includes capital markets and corporate updates, such as underwritten public offerings of Class A common stock, at-the-market sales agreements, inducement equity grants under the company’s 2024 Inducement Plan, and changes in board composition or executive roles disclosed via Form 8-K. Vera Therapeutics also announces participation in healthcare and investor conferences, where its management team presents clinical data and corporate strategy.
By reviewing the VERA news page regularly, readers can track how clinical milestones, regulatory decisions, financing activities, and governance changes may relate to Vera Therapeutics’ development programs and its position as a late clinical-stage biotech issuer.
Vera Therapeutics (NASDAQ: VERA) priced an underwritten public offering of 6,138,108 Class A shares at $42.50 per share, expected to raise approximately $261 million in gross proceeds before fees.
The company granted underwriters a 30-day option to buy up to an additional 920,716 shares at the public offering price. The offering is expected to close on December 11, 2025, subject to customary closing conditions. Joint book-runners include J.P. Morgan, Goldman Sachs, Evercore ISI and Cantor; LifeSci Capital is lead manager.
Vera Therapeutics (NASDAQ: VERA) announced on December 8, 2025 its intention to commence a public offering to issue and sell $200.0 million of Class A common stock, subject to market and other conditions.
The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares. The offering will be made from an existing Form S-3 shelf registration that became effective October 28, 2024, and a preliminary prospectus supplement will be filed with the SEC.
Vera Therapeutics (Nasdaq: VERA) announced that on December 2, 2025 its Compensation Committee granted inducement awards under the 2024 Inducement Plan to seven new employees. The awards include non-qualified stock options to purchase 42,000 shares and restricted stock units underlying 21,000 shares of Class A common stock.
Each option has an exercise price of $37.25 (Vera's closing price on December 2, 2025) and vests over four years (25% after one year, then monthly over 36 months). RSUs vest over four years with 25% vesting on each anniversary of November 20, 2025. Awards are subject to the Inducement Plan and applicable award agreements.
Vera Therapeutics (Nasdaq: VERA) announced the appointment of James R. Meyers to its Board of Directors on November 26, 2025. Meyers brings over 30 years of commercial leadership, including senior roles at Gilead and AstraZeneca, plus CEO experience at IntraBio and current board seats at Sangamo and CytomX.
Management said Meyers will support Vera as it prepares to launch atacicept next year as a potential first-in-class dual BAFF/APRIL inhibitor targeting IgA nephropathy and other autoimmune diseases.
Vera Therapeutics (Nasdaq: VERA) announced that management will present and hold one-on-one meetings at two investor conferences in early December 2025.
Events and logistics:
- Evercore Healthcare Conference — Fireside chat and 1x1s on Dec 2, 2025 at 8:45am ET in Coral Gables, FL; webcast: https://wsw.com/webcast/evercore52/vera/2362844
- Citi 2025 Global Healthcare Conference — Fireside chat and 1x1s on Dec 3, 2025 at 4:00pm ET in Miami, FL; webcast: https://kvgo.com/global-healthcare-conference-2025/vera-therapeutics-december-2025
A replay of the webcasts will be available for 90 days via the company’s Investor Calendar.
Vera Therapeutics (Nasdaq: VERA) announced that its management team will present at the TD Cowen Immunology & Inflammation Summit, held virtually on November 12-13, 2025. The company presentation is scheduled for Thursday, November 13, 2025 at 1:30pm ET.
Management will also hold one-on-one investor meetings. A live webcast is available at the provided link and a replay will be accessible for 90 days via the company’s Investor Calendar.
Vera Therapeutics (NASDAQ: VERA) submitted a BLA through the FDA Accelerated Approval Program for atacicept to treat adults with immunoglobulin A nephropathy (IgAN) on November 7, 2025.
Submission is supported by a prespecified interim analysis of the Phase 3 ORIGIN 3 trial showing a 46% reduction from baseline in 24‑hour UPCR and a 42% reduction versus placebo at week 36 (p<0.0001). The company reports a favorable safety profile comparable to placebo. ORIGIN 3 enrolled 431 adults and remains blinded to assess eGFR over two years, with trial completion expected in 2027.
Vera Therapeutics (Nasdaq: VERA) announced that on November 4, 2025 its Compensation Committee granted inducement awards to six new employees under the 2024 Inducement Plan.
The awards include non-qualified stock options to purchase 79,050 shares and restricted stock units covering 39,915 shares. Each option has an exercise price of $24.35, equal to Vera Therapeutics’ closing price on November 4, 2025.
Vesting: options vest over four years with 25% on the first anniversary then monthly over 36 months; RSUs vest over four years with 25% vesting on each anniversary beginning November 20, 2025. Awards are subject to the Inducement Plan and applicable award agreements and were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (Nasdaq: VERA) reported positive ORIGIN Phase 3 interim data for atacicept in IgA nephropathy presented at ASN Kidney Week 2025 and published in NEJM.
At week 36 atacicept produced a 46% reduction from baseline in UPCR and a 42% reduction versus placebo (p<0.0001). Secondary results included Gd-IgA1 reduced 68% and hematuria resolved in 81% of participants with baseline hematuria. Safety across the ORIGIN program was described as comparable to placebo, with fewer serious adverse events (1 [0.5%] atacicept vs 11 [5%] placebo) and no deaths.
The company plans a BLA submission via Accelerated Approval in Q4 2025 with a potential PDUFA date in 2026; the ORIGIN 3 trial (N=431) remains blinded to assess two-year eGFR results expected in 2027.
Vera Therapeutics (NASDAQ: VERA) reported Q3 2025 results and a business update ahead of ASN Kidney Week 2025. The company will present 36‑week ORIGIN 3 primary endpoint results as a late‑breaking oral presentation on November 6, 2025, with two additional posters also scheduled.
Vera expects to submit a BLA for atacicept in IgA nephropathy to the U.S. FDA via the Accelerated Approval Program in Q4 2025, with a potential U.S. commercial launch in 2026. Ongoing trials include PIONEER, a monthly dose range finding study, and ORIGIN Extend. Initial PIONEER results are expected in Q4 2025; 2‑year ORIGIN 3 data are expected in 2027.
Financials: Q3 net loss was $80.3M ($1.26/diluted share); nine‑month operating cash use was $171.1M. Cash, equivalents, and marketable securities totaled $497.4M as of September 30, 2025.